Clinical Trial Update: Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults [Phase 2]

View source ↗

Summary

A Phase 2 safety, immunogenicity and efficacy trial evaluating an inactivated whole-cell Shigella flexneri 2a vaccine with and without dmLT has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Double-mutant LT adjuvant (dmLT) (dmLT adjuvant)
• Inactivated Whole Cell Shigella flexneri 2a vaccine (Inactivated whole-cell Shigella flexneri 2a vaccine)

Snippet

Sponsor: PATH | Conditions: Shigella Sonnei Dysenteries | Phase 2 | Status: WITHDRAWN